Torrent Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Capri Global Capital Ltd, Marico Ltd, Honeywell Automation India Ltd, Laxmi Organic Industries Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2024.

Torrent Pharmaceuticals Ltd registered volume of 106.33 lakh shares by 10:47 IST on BSE, a 2179.99 fold spurt over two-week average daily volume of 4878 shares. The stock slipped 2.38% to Rs.3,134.50. Volumes stood at 7419 shares in the last session.

Capri Global Capital Ltd clocked volume of 3.17 lakh shares by 10:47 IST on BSE, a 34.85 times surge over two-week average daily volume of 9093 shares. The stock gained 13.53% to Rs.209.80. Volumes stood at 5128 shares in the last session.

Marico Ltd recorded volume of 1.91 lakh shares by 10:47 IST on BSE, a 9.7 times surge over two-week average daily volume of 19653 shares. The stock gained 3.87% to Rs.653.15. Volumes stood at 26022 shares in the last session.

Honeywell Automation India Ltd witnessed volume of 744 shares by 10:47 IST on BSE, a 4.3 times surge over two-week average daily volume of 173 shares. The stock dropped 7.54% to Rs.45,297.20. Volumes stood at 128 shares in the last session.

Laxmi Organic Industries Ltd saw volume of 2.9 lakh shares by 10:47 IST on BSE, a 4.05 fold spurt over two-week average daily volume of 71540 shares. The stock increased 8.61% to Rs.274.35. Volumes stood at 83736 shares in the last session.

Powered by Capital Market - Live News

Revenue from operations rose 8.60% year on year (YoY) to Rs 2,889 crore in the quarter ended 30 September 2024.

Profit before tax stood at Rs 661 crore in September 2024 quarter, up 18.24% from Rs 559 crore posted in same quarter last year.

Operating EBITDA stood at Rs 939 crore in Q2 FY25, registering a growth of 13.81% as against Rs 825 crore reported in Q2 FY24.

The company's India revenue grew by 13% YoY to Rs 1,632 crore in Q2 FY25, led by outperformance in focus therapies. As per All India Organization of Chemists & Druggists (AIOCD) secondary market data, IPM growth for the quarter was 8%. Torrent’s chronic business grew at 14% versus IPM growth of 9%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches.

Torrent Pharma's Brazil revenue rose by 4% to Rs 263 crore and on constant currency terms revenues was up by 17% at R$ 174 million. As per IQVIA, market growth for the quarter was 8%. Growth was aided by performance of top brands, new launches and growth in generic segment.

The Germany revenue stood at Rs 288 crore, by 8%. Constant currency revenue at Euro 31 million was up by 6%. Growth momentum continues with incremental tender wins since last five quarters.

The company's US revenue stood at Rs 268 crore in Q2 FY25, up by 8%. Constant currency revenue was at $32 million, up by 7% YoY. Sequential quarter sales were at a similar level.

Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology.

Shares of Torrent Pharmaceuticals rallied 3.63% to end at Rs 3,436.65 on the BSE.

Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 17.36% to Rs 453.00 crore in the quarter ended September 2024 as against Rs 386.00 crore during the previous quarter ended September 2023. Sales rose 7.72% to Rs 2831.00 crore in the quarter ended September 2024 as against Rs 2628.00 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 25 October 2024.

Powered by Capital Market - Live News